A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly

Trial Profile

A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Pasireotide (Primary) ; Insulin; Liraglutide; Metformin; Sitagliptin
  • Indications Acromegaly; Pituitary ACTH hypersecretion
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 29 Jun 2018 to 11 Jun 2018.
    • 12 Oct 2017 Planned primary completion date changed from 29 Jun 2018 to 11 Jun 2018.
    • 12 Oct 2017 This trial has been completed in Germany as per Eudra.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top